Biomarkers in Atopic Dermatitis and Psoriasis

Atopic dermatitis and psoriasis aﬀect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment.

Resulting in signiﬁcant morbidity and an increased risk for associated conditions such as arthritis and asthma, inﬂammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems.

BIOMAP will examine the causes and mechanisms of these conditions by identifying the biomarkers responsible for the variation in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics.

60 months

60 months

12 countries
31 Partners

12 countries

20.8 Mio €

20.8 Mio €

Areas of focus


BIOMAP is a collaborative network of clinicians, researchers and industry along with patient organisations and other stakeholders

Molecular Profiling

BIOMAP will provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular proﬁling


BIOMAP will investigate causes and mechanisms of Atopic Dermatitis and Psoriasis


BIOMAP will collect data from diﬀerent clinical and epidemiological studies, registries and trials to deﬁne disease endotypes

Voices of BIOMAP